UID:
edocfu_9961565605502883
Format:
1 online resource (361 pages).
ISBN:
0-226-61123-X
Series Statement:
National Bureau of Economic Research Conference Report
Content:
Personalized and precision medicine (PPM)-the targeting of therapies according to an individual's genetic, environmental, or lifestyle characteristics-is becoming an increasingly important approach in health care treatment and prevention. The advancement of PPM is a challenge in traditional clinical, reimbursement, and regulatory landscapes because it is costly to develop and introduces a wide range of scientific, clinical, ethical, and socioeconomic issues. PPM raises a multitude of economic issues, including how information on accurate diagnosis and treatment success will be disseminated and who will bear the cost; changes to physician training to incorporate genetics, probability and statistics, and economic considerations; questions about whether the benefits of PPM will be confined to developed countries or will diffuse to emerging economies with less developed health care systems; the effects of patient heterogeneity on cost-effectiveness analysis; and opportunities for PPM's growth beyond treatment of acute illness, such as prevention and reversal of chronic conditions. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM.
Note:
Also issued in print: 2019.
,
Frontmatter --
,
Contents --
,
Acknowledgment --
,
Introduction --
,
1. The Economic Value and Pricing of Personalized Medicine --
,
2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS --
,
3. The Value of Pharmacogenomic Information --
,
4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory --
,
5. Characterizing the Drug Development Pipeline for Precision Medicines --
,
6. Cost Sharing in Insurance Coverage for Precision Medicine --
,
7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments --
,
8. Physicians' Financial Incentives to Personalize Medicine --
,
9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan --
,
10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger --
,
11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies --
,
Contributors --
,
Author Index --
,
Subject Index
,
In English.
Additional Edition:
ISBN 0-226-61106-X
Language:
English
Subjects:
Economics
DOI:
10.7208/9780226611235
Bookmarklink
